Camidanlumab tesirine

Camidanlumab tesirine (ADCT 301) is an ADC comprising HuMax-TAC, a human IgG1 mAb directed against human CD25, stochastically conjugated through a dipeptide cleavable linker to a pyrrolobenzodiazepine (PBD) dimer warhead. Camidanlumab tesirine has a drug–antibody ratio (DAR) of 2.3. Camidanlumab tesirine binds human CD25 with picomolar affinity. Camidanlumab tesirine has highly potent and selective cytotoxicity against a panel of CD25-expressing human lymphoma cell lines[1].

Product Specifications

CAS Number

[1853239-04-9]

Product Name Alternative

ADCT 301

UNSPSC

12352100

Target

Antibody-Drug Conjugates (ADCs) ; Interleukin Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

96.52

Solubility

10 mM in DMSO

Smiles

[Camidanlumabtesirine]

References & Citations

[1]Michael J Flynn, et al. ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Mol Cancer Ther. 2016 Nov;15 (11) :2709-2721.|[2]Francesca Zammarchi, et al. CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity. J Immunother Cancer. 2020 Sep;8 (2) :e000860.